SE0400970D0 - Nicotinic acetylcholine receptor ligands - Google Patents

Nicotinic acetylcholine receptor ligands

Info

Publication number
SE0400970D0
SE0400970D0 SE0400970A SE0400970A SE0400970D0 SE 0400970 D0 SE0400970 D0 SE 0400970D0 SE 0400970 A SE0400970 A SE 0400970A SE 0400970 A SE0400970 A SE 0400970A SE 0400970 D0 SE0400970 D0 SE 0400970D0
Authority
SE
Sweden
Prior art keywords
acetylcholine receptor
nicotinic acetylcholine
receptor ligands
compounds
medicaments
Prior art date
Application number
SE0400970A
Other languages
English (en)
Swedish (sv)
Inventor
Marc Chapdelaine
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0400970A priority Critical patent/SE0400970D0/xx
Publication of SE0400970D0 publication Critical patent/SE0400970D0/xx
Priority to BRPI0509777-0A priority patent/BRPI0509777A/pt
Priority to RU2006135481/04A priority patent/RU2372350C2/ru
Priority to CNA2005800194932A priority patent/CN1968951A/zh
Priority to EP05722314A priority patent/EP1737854A1/en
Priority to CA002563010A priority patent/CA2563010A1/en
Priority to PCT/SE2005/000500 priority patent/WO2005100351A1/en
Priority to AU2005233492A priority patent/AU2005233492B2/en
Priority to JP2007508300A priority patent/JP2007532637A/ja
Priority to US10/599,839 priority patent/US7566727B2/en
Priority to UAA200610315A priority patent/UA86617C2/ru
Priority to IL178241A priority patent/IL178241A0/en
Priority to ZA200608412A priority patent/ZA200608412B/xx
Priority to NO20065199A priority patent/NO20065199L/no
Priority to RU2009126341/04A priority patent/RU2009126341A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SE0400970A 2004-04-14 2004-04-14 Nicotinic acetylcholine receptor ligands SE0400970D0 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE0400970A SE0400970D0 (sv) 2004-04-14 2004-04-14 Nicotinic acetylcholine receptor ligands
US10/599,839 US7566727B2 (en) 2004-04-14 2005-04-06 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydro-isoindole-1-one/5,6-dihydro-furo[2,3-c] pyrrol-4-one derivative ligands for alpha 7 nicotinic acetylcholine receptor
PCT/SE2005/000500 WO2005100351A1 (en) 2004-04-14 2005-04-06 NOVEL 2-(1-AZA-BICYCLO[2.2.2]OCT-3-yl)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
JP2007508300A JP2007532637A (ja) 2004-04-14 2005-04-06 α７ニコチン性アセチルコリン受容体に対する新規な２−（１−アザ−ビシクロ［２．２．２］オクタ−３−イル）−２，３−ジヒドロイソインドール−１−オン／５，６−ジヒドロ−フロ［２，３−ｃ］ピロール−４−オン誘導体リガンド
CNA2005800194932A CN1968951A (zh) 2004-04-14 2005-04-06 α 7烟碱乙酰胆碱受体的新颖 2 －( 1 －氮杂 －二环 [ 2 . 2 . 2 ]辛－ 3 －基 ) － 2 , 3 －二氢 －异吲哚 － 1 －酮 / 5 , 6 －二氢－呋喃并 [ 2 , 3 － C ]吡咯 －4 －酮衍生物配体
EP05722314A EP1737854A1 (en) 2004-04-14 2005-04-06 NOVEL 2-(1-AZA-BICYCLO[2.2.2]OCT-3-yl)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
CA002563010A CA2563010A1 (en) 2004-04-14 2005-04-06 Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-1-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
BRPI0509777-0A BRPI0509777A (pt) 2004-04-14 2005-04-06 composto, métodos de tratamento ou profilaxia de doenças ou condições e de distúrbios, método para induzir o parar de fumar, composição farmacêutica, e, uso de um composto,um enantiÈmero do mesmo ou um sal farmaceuticamente aceitável do mesmo
AU2005233492A AU2005233492B2 (en) 2004-04-14 2005-04-06 Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-l-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
RU2006135481/04A RU2372350C2 (ru) 2004-04-14 2005-04-06 НОВЫЕ ПРОИЗВОДНЫЕ 2-(1-АЗА-БИЦИКЛО[2.2.2]ОКТ-3-ИЛ)-2,3-ДИГИДРОИЗОИНДОЛ-1-ОНА/5,6-ДИГИДРО-ФУРО[2,3-c]ПИРРОЛ-4-ОНА В КАЧЕСТВЕ ЛИГАНДОВ К АЛЬФА 7 НИКОТИНОВОМУ АЦЕТИЛХОЛИНОВОМУ РЕЦЕПТОРУ
UAA200610315A UA86617C2 (en) 2004-04-14 2005-06-04 2-(1-AZA-BICYCLO[2.2.2]OCT-3-YL)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4-ONE DERIVATIVES AS LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
IL178241A IL178241A0 (en) 2004-04-14 2006-09-21 NOVEL 2 - (1 - AZA - BICYCLO [2.2.2] OCT - 3 - YL) - 2, 3 - DIHYDROISOINDOL - 1 - ONE /5, 6 - DIHYDRO - FURO [2, 3 - c] PYRROL - 4 - ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
ZA200608412A ZA200608412B (en) 2004-04-14 2006-10-09 Novel 2-[1-aza-bicyclo (2.2.2)oct-3-yl)-2,3-dihydroisoindol-1-one/5/6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
NO20065199A NO20065199L (no) 2004-04-14 2006-11-13 Nye 2-(1-aza-bicyklo[2.2.2]okt-3-yl)-2,3-dihydroisoindol-1-on/5,6-dihydro-furo[2,3-c]pyrrol-4-on derivater ligander for alfa 7 nikotinacetylcholin reseptor
RU2009126341/04A RU2009126341A (ru) 2004-04-14 2009-07-10 НОВЫЕ ПРОИЗВОДНЫЕ 2-(1-АЗА-БИЦИКЛО[2.2.2.]ОКТ-3-ИЛ)-2,3-ДИГИДРОИЗОИНДОЛ-1-ОНА/5,6-ДИГИДРО-ФУРО[2,3-c]ПИРРОЛ-4-ОНА В КАЧЕСТВЕ ЛИГАНДОВ К АЛЬФА 7 НИКОТИНОВОМУ АЦЕТИЛХОЛИНОВОМУ РЕЦЕПТОРУ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0400970A SE0400970D0 (sv) 2004-04-14 2004-04-14 Nicotinic acetylcholine receptor ligands

Publications (1)

Publication Number Publication Date
SE0400970D0 true SE0400970D0 (sv) 2004-04-14

Family

ID=32294312

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0400970A SE0400970D0 (sv) 2004-04-14 2004-04-14 Nicotinic acetylcholine receptor ligands

Country Status (14)

Country Link
US (1) US7566727B2 (enExample)
EP (1) EP1737854A1 (enExample)
JP (1) JP2007532637A (enExample)
CN (1) CN1968951A (enExample)
AU (1) AU2005233492B2 (enExample)
BR (1) BRPI0509777A (enExample)
CA (1) CA2563010A1 (enExample)
IL (1) IL178241A0 (enExample)
NO (1) NO20065199L (enExample)
RU (2) RU2372350C2 (enExample)
SE (1) SE0400970D0 (enExample)
UA (1) UA86617C2 (enExample)
WO (1) WO2005100351A1 (enExample)
ZA (1) ZA200608412B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
WO2009042907A1 (en) * 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
KR101758046B1 (ko) * 2009-12-22 2017-07-14 버텍스 파마슈티칼스 인코포레이티드 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제
KR20120125618A (ko) 2009-12-31 2012-11-16 피라말 헬쓰케어 리미티드 디아실글리세롤 아실 전이효소의 억제제
JO3383B1 (ar) * 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
US10329289B2 (en) 2015-12-23 2019-06-25 Merck Sharp & Dohme Corp. 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
KR20190093205A (ko) 2016-12-21 2019-08-08 바이오테릭스, 인코포레이티드 단백질 표적화에 사용하기 위한 티에노피롤 유도체, 조성물, 방법 및 이의 용도
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018210229A1 (zh) * 2017-05-18 2018-11-22 南京明德新药研发股份有限公司 α-7尼古丁乙酰胆碱受体激动剂及应用
CN107188900B (zh) * 2017-05-27 2019-09-06 北京师范大学 α7烟碱型乙酰胆碱受体的配体化合物及其应用
WO2018226545A1 (en) * 2017-06-09 2018-12-13 Merck Sharp & Dohme Corp. Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
EP4251149A4 (en) * 2020-11-24 2024-10-30 Merck Sharp & Dohme LLC MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
SE9201478D0 (sv) * 1992-05-11 1992-05-11 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
IT1303123B1 (it) * 1998-10-13 2000-10-30 Rotta Research Lab Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
ATE385497T1 (de) * 2000-12-01 2008-02-15 Neurosearch As 3-substituierte quinuclidin-derivate und deren verwendung als nikotinischen agonisten
DE10118551A1 (de) * 2001-04-14 2002-10-17 Merck Patent Gmbh Nikotinische Acetylcholinrezeptor Liganden
NZ529880A (en) * 2001-07-06 2005-09-30 Neurosearch As Novel compounds, their preparation and use
EP1532144B1 (en) * 2002-08-14 2008-01-23 Neurosearch A/S quinuclidine derivatives and their use

Also Published As

Publication number Publication date
RU2006135481A (ru) 2008-05-20
US7566727B2 (en) 2009-07-28
IL178241A0 (en) 2006-12-31
NO20065199L (no) 2006-11-13
WO2005100351A1 (en) 2005-10-27
RU2372350C2 (ru) 2009-11-10
US20070213342A1 (en) 2007-09-13
CN1968951A (zh) 2007-05-23
BRPI0509777A (pt) 2007-10-23
AU2005233492A1 (en) 2005-10-27
CA2563010A1 (en) 2005-10-27
RU2009126341A (ru) 2011-01-20
AU2005233492B2 (en) 2009-06-11
ZA200608412B (en) 2008-09-25
UA86617C2 (en) 2009-05-12
JP2007532637A (ja) 2007-11-15
EP1737854A1 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
SE0400970D0 (sv) Nicotinic acetylcholine receptor ligands
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
WO2008130320A3 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
BR122013028005B8 (pt) compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica, kit e forma de dosagem oral compreendendo os referidos compostos, uso das referidas composições, bem como processo de preparação dos referidos compostos
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
TW200833670A (en) Novel compounds 569
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
TW200806299A (en) Treatment of pain
SE0403171D0 (sv) New compounds
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE446089T1 (de) 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika
TW200716529A (en) New compounds II
IN2012DN00785A (enExample)
WO2007125398A3 (en) : sulfonamide compounds as antagonists of the n-type calcium channel
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
TW200745122A (en) New compounds I
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease